Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of ribociclib plus non-steroidal aromatase inhibitor in elderly patients with HR+/HER2- advanced breast cancer
2018-002514-12Phase 2Terminated
- Sponsor
- Fondazione Sandro Pitigliani
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Fondazione Sandro Pitigliani. Primary endpoint: Treatment feasibility at 6 months. Started Jan 2021; status: terminated.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-002514-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002514-12.